Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X:
“Biochemical recurrence isn’t just relapse!
Next-gen imaging like PSMA PET now reveals “PSMA+BCR,” a hidden state between local and metastatic disease. The NCI Working Group urges trials to rethink control arms, endpoints, and toxicity, less intensity, more precision.”
Title: National Cancer Institute’s Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations
Authors: David J. Einstein, Melissa L. Abel, Jeanny B. Aragon-Ching, Philip M. Arlen, Karen A. Autio, Marijo Bilusic, Michael A. Carducci, Peter L. Choyke, Deborah E. Citrin, William D. Figg, Julie N. Graff, James L. Gulley, Susan Halabi, Fatima Karzai, Liza Lindenberg, Mark C. Markowski, Catherine H. Marshall, Douglas G. McNeel, Esther Mena, Helen Moon, Russell K. Pachynski, Channing J. Paller, Krishnan R. Patel, Edwin M. Posadas, Kenneth J. Pienta, Meredith M. Regan, Laura A. Sena, Charlotte S. Walmsley, Xiao X. Wei, Evan Y. Yu, Phuoc T. Tran, Ravi A. Madan

More posts featuring Yüksel Ürün on OncoDaily.